Financials Intervacc AB

Equities

IVACC

SE0009607252

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 12:00:00 2024-06-26 EDT 5-day change 1st Jan Change
3.18 SEK -2.45% Intraday chart for Intervacc AB +0.63% -49.76%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 781.4 2,648 2,669 1,313 479.4 240.8 - -
Enterprise Value (EV) 1 729.3 2,485 2,553 1,267 391.2 120.8 165.8 196.8
P/E ratio -25.4 x -97.8 x -90.2 x -20.3 x -3.75 x -3.46 x -3.98 x -5.48 x
Yield - - - - - - - -
Capitalization / Revenue 64.4 x 554 x 509 x 136 x 59.8 x 12.4 x 4.54 x 2.08 x
EV / Revenue 60.1 x 520 x 487 x 131 x 48.8 x 6.2 x 3.12 x 1.7 x
EV / EBITDA -33.6 x -127 x -110 x -29.1 x -5.67 x -2.46 x -4.68 x -12.9 x
EV / FCF -17.5 x -78.9 x -53.3 x -16.7 x -8.16 x -2.01 x -3.53 x -6.15 x
FCF Yield -5.72% -1.27% -1.88% -5.99% -12.3% -49.7% -28.3% -16.3%
Price to Book 3.55 x 7.84 x 8.66 x 5.25 x 2.01 x 0.92 x 1.15 x 1.37 x
Nbr of stocks (in thousands) 43,293 50,160 50,160 50,491 75,736 75,736 - -
Reference price 2 18.05 52.80 53.20 26.00 6.330 3.180 3.180 3.180
Announcement Date 20-02-21 21-02-18 22-02-18 23-02-17 24-02-16 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 12.14 4.78 5.241 9.684 8.015 19.5 53.1 115.7
EBITDA 1 -21.69 -19.5 -23.24 -43.56 -68.98 -49.1 -35.4 -15.3
EBIT 1 -27.85 -25.68 -29.39 -64.41 -93.58 -71.6 -62 -43.2
Operating Margin -229.41% -537.15% -560.83% -665.15% -1,167.55% -367.18% -116.76% -37.34%
Earnings before Tax (EBT) 1 -27.89 -25.6 -29.38 -64.16 -91.46 -70 -60 -42
Net income 1 -27.89 -25.6 -29.38 -64.16 -102.9 -70 -60 -44
Net margin -229.77% -535.59% -560.48% -662.52% -1,283.24% -358.97% -112.99% -38.03%
EPS 2 -0.7100 -0.5400 -0.5900 -1.280 -1.690 -0.9200 -0.8000 -0.5800
Free Cash Flow 1 -41.73 -31.5 -47.9 -75.92 -47.94 -60 -47 -32
FCF margin -343.78% -658.97% -913.95% -783.99% -598.14% -307.69% -88.51% -27.66%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 20-02-21 21-02-18 22-02-18 23-02-17 24-02-16 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3
Net sales 1 2.18 - 2.612 2.016
EBITDA 1 - - -9.805 -8.612
EBIT 1 -8.798 - -15.74 -14.58
Operating Margin -403.58% - -602.57% -723.36%
Earnings before Tax (EBT) 1 - - -15.77 -14.62
Net income 1 -8.729 -10.73 -15.77 -14.62
Net margin -400.41% - -603.71% -724.95%
EPS -0.1700 -0.2100 - -
Dividend per Share - - - -
Announcement Date 22-02-18 22-05-20 22-08-31 22-11-10
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 52.1 164 115 45.5 88.2 120 75 44
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -41.7 -31.5 -47.9 -75.9 -47.9 -60 -47 -32
ROE (net income / shareholders' equity) -13.6% -9.19% -9.1% -23% - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 5.080 6.730 6.150 4.950 3.140 3.460 2.770 2.320
Cash Flow per Share - -0.4300 - - - - - -
Capex 1 39.1 11.4 22.4 5.25 0.06 - 1 1
Capex / Sales 322% 238.87% 428.11% 54.22% 0.7% - 1.88% 0.86%
Announcement Date 20-02-21 21-02-18 22-02-18 23-02-17 24-02-16 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. IVACC Stock
  4. Financials Intervacc AB